ADMS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States...

Stats
Today's Volume	3.15M
Average Volume	1.34M
Market Cap	0.00
EPS	$-0.430 ( 2021-11-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.189 (2.30%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-24	Mahoney David L	Sell	112 781	Common Stock
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	40 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 2 100 832 \| Sell: 2 425 856

Volume Correlation

Long: 0.29 (neutral)

Short: 0.76 (moderate)

Signal:(73.528) Neutral

Adamas Pharmaceuticals Correlation

10 Most Positive Correlations
SLNO	0.983
BRACU	0.965
XLRN	0.964
LABP	0.962
HCTI	0.961
IMVT	0.959
CYT	0.956
ZYNE	0.951
GTH	0.95
LIQT	0.949

10 Most Negative Correlations
AGZD	-0.992
DXJS	-0.988
UNAM	-0.962
MORF	-0.958
BAFN	-0.945
PEBK	-0.941
AHPI	-0.94
ATSG	-0.94
EDSA	-0.939
PI	-0.939

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Adamas Pharmaceuticals Correlation - Currency/Commodity

-0.55
( weak negative )

-0.53
( weak negative )

0.20
( neutral )

-0.12
( neutral )

0.78
( moderate )

Adamas Pharmaceuticals Financials

Annual	2020
Revenue:	$74.46M
Gross Profit:	$72.42M (97.26 %)
EPS:	$-1.632

Q3	2021
Revenue:	$25.90M
Gross Profit:	$25.32M (97.78 %)
EPS:	$-0.430

Q2	2021
Revenue:	$21.97M
Gross Profit:	$21.45M (97.60 %)
EPS:	$-0.270

Q1	2021
Revenue:	$19.31M
Gross Profit:	$18.93M (98.01 %)
EPS:	$-0.360

Financial Reports:

No articles found.

Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.